Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HBV-MPL vaccine Formulation A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | HBV-MPL Formulation A at months 0 and 6 |
| Group B | EXPERIMENTAL | HBV-MPL Formulation B at months 0 and 6 |
| Group C | EXPERIMENTAL | HBV-MPL Formulation A at month 0 and Engerix™-B at month 6 |
| Group D | ACTIVE_COMPARATOR | Engerix™-B at months 0, 1, 6 |
| Name | Type | Description |
|---|---|---|
| HBV-MPL vaccine Formulation A | BIOLOGICAL | Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection |
| HBV-MPL vaccine Formulation B | BIOLOGICAL | 2-dose intramuscular injection |
| Engerix™-B | BIOLOGICAL | Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection |
Inclusion Criteria: * Age: between 11 and 15 years at the time of the first vaccination. * Free of obvious health problems as established by medical history and clinical examination before entering into the study. * Written informed consent obtained from the parents or guardians of the subject and ...
HBV-MPL vaccine Formulation A is an investigational vaccine being studied for the prevention of Hepatitis B. It is currently in Phase 2 clinical development and is intended for use in healthy adolescents. The vaccine is being evaluated for its safety and immunogenicity compared to an active control.
HBV-MPL vaccine Formulation A is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in healthy adolescents for the prevention of Hepatitis B.
HBV-MPL vaccine Formulation A is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the vaccine is being studied for its safety and immunogenicity in healthy adolescents for Hepatitis B.
HBV-MPL vaccine Formulation A has been studied in one completed Phase 2 clinical trial with the identifier NCT00697775. The trial, titled 'Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents,' enrolled 200 participants in Germany and was an active-controlled, randomized study.
No, HBV-MPL vaccine Formulation A is not the same as Engerix-B. Engerix-B is a licensed Hepatitis B vaccine that was used as an active control in the clinical trial for HBV-MPL vaccine Formulation A. The two vaccines are different products, and the trial compared the candidate vaccine against Engerix-B.